{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:15:02Z","timestamp":1791472502006,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eprac.2023.12.010","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T19:17:47Z","timestamp":1702927067000},"page":"292-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management"],"prefix":"10.1016","volume":"30","author":[{"given":"Ashwin Kanna","family":"Chetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebne","family":"Rafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5743-9458","authenticated-orcid":false,"given":"Diana","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2023.12.010_bib1","series-title":"World Obesity Atlas 2023","author":"Lobstein","year":"2023"},{"issue":"2","key":"10.1016\/j.eprac.2023.12.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu13020351","article-title":"Incretin hormones in obesity and related cardiometabolic disorders: the clinical perspective","volume":"13","author":"Micha\u0142owska","year":"2021","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.eprac.2023.12.010_bib3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/biom11101426","article-title":"Obesity\u2013an update on the basic pathophysiology and review of recent therapeutic advances","volume":"11","author":"Gjermeni","year":"2021","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.eprac.2023.12.010_bib4","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s11695-020-04457-9","article-title":"Temporal effects of sleeve gastrectomy on glucose-insulin homeostasis and incretin hormone response at 1 and 6 months","volume":"30","author":"Prior","year":"2020","journal-title":"Obes Surg"},{"key":"10.1016\/j.eprac.2023.12.010_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2023.12.010_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101139","article-title":"Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms","volume":"46","author":"Campbell","year":"2021","journal-title":"Mol Metab"},{"issue":"14","key":"10.1016\/j.eprac.2023.12.010_bib7","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.3390\/ijms20143445","article-title":"Glucagon, GLP-1 and thermogenesis","volume":"20","author":"Gonz\u00e1lez-Garc\u00eda","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.eprac.2023.12.010_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2023.12.010_bib11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes"},{"issue":"7","key":"10.1016\/j.eprac.2023.12.010_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2023.12.010_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity"},{"issue":"5","key":"10.1016\/j.eprac.2023.12.010_bib14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.eprac.2023.12.010_bib23","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A\u00a0randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2023.12.010_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10278","key":"10.1016\/j.eprac.2023.12.010_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.eprac.2023.12.010_bib17","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.eprac.2023.12.010_bib18","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.eprac.2023.12.010_bib19","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eprac.2023.12.010_bib20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.eprac.2023.12.010_bib24","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2023.12.010_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2023.12.010_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10402","key":"10.1016\/j.eprac.2023.12.010_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eprac.2023.12.010_bib26","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.eprac.2023.12.010_bib81","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued teatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"10403","key":"10.1016\/j.eprac.2023.12.010_bib28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2023.12.010_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2023.12.010_bib9","article-title":"FDA-approved pharmacotherapy for weight loss over the last decade","volume":"14","author":"Idrees","year":"2022","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.eprac.2023.12.010_bib36","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the scale sleep apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"12","key":"10.1016\/j.eprac.2023.12.010_bib35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.eprac.2023.12.010_bib34","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2023.12.010_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes Sci Pract"},{"issue":"8","key":"10.1016\/j.eprac.2023.12.010_bib71","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1007\/s11695-021-05394-x","article-title":"What is weight loss after bariatric surgery expressed in percentage total weight loss (%TWL)? A systematic review","volume":"31","author":"van Rijswijk","year":"2021","journal-title":"Obes Surg"},{"issue":"10","key":"10.1016\/j.eprac.2023.12.010_bib73","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2023.12.010_bib74","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2023.12.010_bib75","doi-asserted-by":"crossref","DOI":"10.2337\/db23-51-OR","article-title":"Hennige AM. 51-OR: a phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with overweight\/obesity","volume":"72","author":"Le Roux","year":"2023","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2023.12.010_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.eprac.2023.12.010_bib78","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jaip.2014.05.011","article-title":"A\u00a0case report of allergy to exenatide","volume":"2","author":"P\u00e9rez","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.eprac.2023.12.010_bib79","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jdiacomp.2012.05.018","article-title":"Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?","volume":"26","author":"Besemer","year":"2012","journal-title":"J\u00a0Diabetes Complications"},{"issue":"10","key":"10.1016\/j.eprac.2023.12.010_bib80","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1001\/jamadermatol.2019.1893","article-title":"Acute photodistributed exanthematous pustulosis associated with liraglutide treatment","volume":"155","author":"Cogen","year":"2019","journal-title":"JAMA Dermatol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23007905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23007905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:16:39Z","timestamp":1761516999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23007905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1530891X23007905"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.12.010","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}